ArticleDrug safety2022
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.
Johannes M M Boots et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this paperpooled itcites it